Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul 1;204(1):7-9.
doi: 10.1164/rccm.202103-0674ED.

CFTR Modulators to the Rescue of Individuals with Cystic Fibrosis and Advanced Lung Disease

Mike Myerburg  1 , Joseph M Pilewski  1
Affiliations
Editorial

CFTR Modulators to the Rescue of Individuals with Cystic Fibrosis and Advanced Lung Disease

Mike Myerburg et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effect of elexacaftor–tezacaftor–ivacaftor (ETI) on lung disease in a young man homozygous for 508del CFTR mutations. After his first visit to our center in January 2019, he received nine courses of antibiotics and was evaluated for lung transplantation. Since initiating ETI through a compassionate use program in September 2019, he has not had a cystic fibrosis exacerbation, his FEV1 improved from 26% to 50% predicted, his body mass index improved from 14.5 to 17.6, and he returned to full-time employment. Computed tomographic imaging in October 2019 (right), after 1 month of ETI, demonstrated marked reduction in areas of mucus impaction compared with before (left).
See this image and copyright information in PMC

Comment on

References

    1. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672. - PMC - PubMed
    1. Barry PJ, Plant BJ, Nair A, Bicknell S, Simmonds NJ, Bell NJ, et al. Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease. Chest. 2014;146:152–158. - PubMed
    1. Polenakovik HM, Sanville B. The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D) J Cyst Fibros. 2013;12:530–531. - PubMed
    1. Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM. VX11-770-901 investigators. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States. J Cyst Fibros. 2016;15:116–122. - PubMed
    1. Salvatore D, Terlizzi V, Francalanci M, Taccetti G, Messore B, Biglia C, et al. Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function. Respir Med. 2020;171:106073. - PubMed

MeSH terms

Substances